查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1951213

標靶定序和定序市場－全球產業規模、佔有率、趨勢、機會及預測（按技術、類型、應用、最終用途、地區和競爭格局分類，2021-2031年）

Targeted Sequencing And Resequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Sequencing, Re-sequencing), By Type, By Application, By End use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球標靶定序和重定序市場預計將從 2025 年的 62.6 億美元成長到 2031 年的 88.8 億美元，複合年成長率為 6.01%。

這些專注於分離和分析特定基因組區域的技術，能夠實現深度且精準的變異識別，並可作為全基因組測序的一種經濟高效的替代方案。推動該技術發展的主要動力是癌症和遺傳疾病發病率的不斷上升，這促使人們需要精準診斷來指導治療方案的選擇。此外，精準腫瘤學藥物研發的快速發展也支持了這項需求，因為基因組數據對於患者分層至關重要。正如個人化醫療聯盟在2024年指出的那樣，FDA在2023年核准了26種新型個人化藥物，這表明人們對指導這些治療所需的標靶診斷有著強烈的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 62.6億美元
市場規模：2031年 88.8億美元
複合年成長率：2026-2031年 6.01%
成長最快的細分市場 定序
最大的市場 北美洲

然而，該市場在生物資訊學和數據解讀方面面臨許多障礙。高通量定序產生的大量複雜數據需要先進的計算基礎設施和專業技能，才能將原始的基因資訊轉化為可操作的臨床見解。這項需求構成了嚴重的瓶頸，阻礙了這些技術在資源匱乏環境中的廣泛應用。

市場促進因素

精準醫療和個人化治療的快速普及正在從根本上改變全球靶向測序和重測序市場，尤其是在腫瘤學領域。隨著臨床醫生越來越重視基因組分析以實現個體化治療，能夠識別特定突變（例如 EGFR 和 BRCA）的靶向檢測組合的需求正以前所未有的速度成長。這種轉變源於全球疾病負擔的日益加重，這需要擴充性且精準的診斷解決方案來有效管理患者照護。例如，根據美國癌症協會預測，到 2024 年，美國新增癌症病例將首次超過 200 萬例，凸顯了先進基因組分析工具的重要性。因此，診斷服務提供者正在迅速擴展其癌症特異性檢測套組，以滿足不斷成長的臨床需求。根據 Natera 公司於 2024 年 8 月發布的“2024 年第二季度財務業績報告”，該公司在 2024 年第二季度進行了約 125,400 次腫瘤檢測，與去年同期相比顯著成長了 50.2%。

同時，用於非侵入性監測的液態生物檢體應用正在擴大市場覆蓋率和效用。標靶定序是這些檢測的基礎技術，它無需進行侵入性組織取樣，即可高靈敏度地檢測循環腫瘤DNA (ctDNA)，用於微量殘存疾病(MRD) 評估和復發監測。這項應用不僅在臨床領域，而且在藥物研發領域也備受關注，並且擴大被用於簡化藥物發現流程和對臨床試驗中的患者進行分層。 Guardant Health 於 2024 年 8 月發布的「2024 年第二季財務業績」反映了這一趨勢，報告顯示，與上年相比，其為生物製藥客戶進行的檢測數量成長了 56%，凸顯了基於液態生物檢體的靶向測序在支持下一代治療治療方法發現方面日益成長的依賴性。

市場挑戰

全球標靶定序和定序市場成長的主要障礙在於生物資訊學和數據解讀的複雜性。雖然標靶定序產生的數據總量小於全基因組分析方法，但它產生的資料集密集且複雜，需要強大的計算基礎設施進行處理。主要瓶頸出現在下游分析階段，實驗室必須準確區分致病變異和良性噪音。這項任務需要複雜的生物資訊演算法和經過專門培訓的人員進行結果檢驗，造成資源短缺，延長診斷週期並增加檢測營運成本。

此外，缺乏標準化的數據框架加劇了這些挑戰，分散的資訊系統難以與電子健康記錄對接。這種整合不足阻礙了醫療服務提供者將原始基因組數據轉化為快速的臨床決策，並限制了該技術在非專業環境中的可擴展性。正如皮斯托亞聯盟在2025年發布的報告所述，數據孤島仍然是實驗室的一大障礙，57%的行業受訪者認為這是有效利用數據和協作的最大障礙。這項技術壁壘直接限制了市場成長，因為它阻礙了定序工作流程與標準醫療實踐的順利整合。

市場趨勢

將人工智慧 (AI) 應用於變異解讀以提高準確性已成為關鍵的市場差異化因素，解決了分析複雜基因組資料集的關鍵瓶頸。隨著高通量定序產生海量原始數據，實驗室正在迅速部署 AI 驅動的生物資訊流程，以自動化變異分類和致病性預測，其速度遠超人工方法。這一趨勢標誌著競爭優勢的結構性價值轉變，從物理定序工作流程轉向下游資料分析和臨床解讀。 Tempus AI 於 2024 年 11 月發布的 2024 年第三季財務業績凸顯了這一轉變，數據顯示數據和業務收益同比成長 64.4%（基因組學收入成長 20.3%），並且越來越依賴 AI 驅動的洞察而非原始定序量。

同時，標靶定序的應用範圍正在癌症診斷之外不斷擴展，使其收入來源不再局限於核心的癌症診斷領域。診斷開發者正在將次世代定序技術應用於心臟病學、免疫學和生殖健康等領域的遺傳性疾病，在這些領域，精準的基因數據對於風險評估和管理至關重要。這種拓展使醫療機構能夠滿足其他專科領域尚未滿足的基因檢測需求，同時降低癌症市場飽和的風險。 Myriard Genetics 在 2024 年 11 月的財報中展示了這項策略的有效性：該公司產前檢測收入同比成長 10%，這主要得益於檢測量的穩步成長以及攜帶者篩檢和無創產前檢測產品報銷條款的改善。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

5. 全球標靶定序與定序市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依技術（定序、定序（基於電泳的定序、NGS、基於晶片的定序））
    • 按類型（基於DNA的標靶定序，基於RNA的標靶定序）
    • 依應用領域（臨床應用、動植物科學、藥物研發等）
    • 依最終使用者（醫院/診所、學術研究機構、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美標靶定序與定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲標靶定序與定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區標靶定序與定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲靶向定序和定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美標靶定序與定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

13. 全球標靶定序與定序市場：SWOT 分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Agilent Technologies Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific, Inc.
  • DNASTAR Inc.
  • Bio-Rad Laboratories, Inc.
  • Integrated DNA Technologies, Inc.
  • Perkin Elmer, Inc.
  • RainDance Technologies, Inc.
  • Genomatix GmbH

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24011

The Global Targeted Sequencing And Resequencing Market is projected to expand from USD 6.26 Billion in 2025 to USD 8.88 Billion by 2031, registering a CAGR of 6.01%. By focusing on isolating and analyzing specific genomic regions, these techniques provide high-depth, accurate variant identification, serving as a cost-efficient alternative to whole-genome sequencing. Growth is fueled largely by the increasing incidence of cancer and genetic conditions, which drives the need for precise diagnostics to guide therapeutic choices. Additionally, the rapid advancement of drug development in precision oncology, where genomic data is essential for patient stratification, supports this demand. As noted by the Personalized Medicine Coalition in 2024, the FDA's approval of 26 new personalized medicines in 2023 indicates strong demand for the targeted diagnostics needed to direct these treatments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.26 Billion
Market Size 2031USD 8.88 Billion
CAGR 2026-20316.01%
Fastest Growing SegmentSequencing
Largest MarketNorth America

However, the market encounters substantial hurdles related to bioinformatics and data interpretation. The massive quantities of complex data produced by high-throughput sequencing demand sophisticated computational infrastructure and specialized skills to convert raw genetic findings into practical clinical insights. This requirement creates a significant bottleneck, impeding the wider adoption of these technologies in settings with limited resources.

Market Driver

The accelerated adoption of precision medicine and personalized therapies is fundamentally reshaping the Global Targeted Sequencing And Resequencing Market, particularly within the oncology sector. As clinicians increasingly prioritize genomic profiling to tailor treatments, the demand for targeted panels that can identify specific mutations-such as EGFR or BRCA-has surged to unprecedented levels. This shift is necessitated by the growing global burden of disease, which requires scalable and precise diagnostic solutions to manage patient care effectively. For instance, according to the American Cancer Society, in 2024, the United States is projected to exceed 2 million new cancer cases for the first time, underscoring the critical need for advanced genomic tools. Consequently, diagnostic providers are witnessing a rapid uptake of their targeted oncology assays to meet this expanding clinical need. According to Natera, Inc., August 2024, in the 'Second Quarter 2024 Financial Results', the company performed approximately 125,400 oncology tests in the second quarter of 2024, representing a significant 50.2% increase compared to the same period in the previous year.

Concurrently, the emergence of liquid biopsy applications for non-invasive monitoring is expanding the market's accessibility and utility. Targeted sequencing is the technological backbone of these assays, enabling the highly sensitive detection of circulating tumor DNA (ctDNA) for minimal residual disease (MRD) assessment and recurrence monitoring without the need for invasive tissue sampling. This application has gained substantial traction not only in clinical settings but also in pharmaceutical research, where it is increasingly used to streamline drug development and stratify patients for clinical trials. Reflecting this trend, according to Guardant Health, August 2024, in the 'Second Quarter 2024 Financial Results', the company reported a 56% year-over-year increase in tests reported to biopharmaceutical customers, highlighting the growing reliance on liquid biopsy-based targeted sequencing for supporting the next generation of therapeutic discoveries.

Market Challenge

A major hurdle inhibiting the growth of the Global Targeted Sequencing And Resequencing Market is the intricacy of bioinformatics and data interpretation. Although targeted sequencing produces less total data than whole-genome approaches, it yields dense, complex datasets that necessitate robust computational infrastructure for processing. The main bottleneck occurs during downstream analysis, where laboratories must precisely differentiate between pathogenic variants and benign noise. This task requires advanced bioinformatic algorithms and expertly trained personnel to verify results, resulting in a resource deficit that extends diagnostic turnaround times and raises the operational costs of testing.

Additionally, the absence of standardized data frameworks worsens these challenges, causing fragmented information systems that struggle to interface with electronic health records. This lack of integration hinders healthcare providers from converting raw genomic data into prompt clinical decisions, thereby restricting the technology's scalability in non-specialized environments. As reported by the Pistoia Alliance in 2025, data silos continue to be a major barrier in laboratories, with 57% of industry respondents citing them as the leading obstacle to effective data usage and collaboration. This technical impediment directly limits market growth by preventing the smooth incorporation of sequencing workflows into standard medical practice.

Market Trends

The integration of Artificial Intelligence for improved variant interpretation is emerging as a key market differentiator, tackling the significant bottleneck of analyzing complex genomic datasets. With high-throughput sequencing producing immense volumes of raw data, laboratories are swiftly implementing AI-driven bioinformatics pipelines to automate variant classification and predict pathogenicity faster than manual methods allow. This trend indicates a structural shift in value, moving competitive advantage from physical sequencing workflows to downstream data analysis and clinical interpretation. Tempus AI's Third Quarter 2024 Financial Results from November 2024 highlight this shift, revealing a 64.4% year-over-year growth in data and services revenue compared to 20.3% in genomics revenue, emphasizing the growing reliance on AI-enabled insights rather than sequencing volume alone.

Concurrently, the application of targeted sequencing is expanding into non-oncology disease areas, diversifying revenue sources beyond the dominant cancer diagnostics sector. Diagnostic developers are adapting next-generation sequencing panels for hereditary conditions in cardiology, immunology, and reproductive health, where precise genetic data is vital for risk assessment and management. This expansion allows providers to offset saturation risks in oncology markets while tapping into the underserved demand for genetic testing in other specialties. Myriad Genetics validated this strategy in its November 2024 financial results, reporting a 10% year-over-year increase in prenatal testing revenue, fueled by strong volume growth and better reimbursement for its carrier screening and non-invasive prenatal products.

Key Market Players

  • Agilent Technologies Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific, Inc.
  • DNASTAR Inc.
  • Bio-Rad Laboratories, Inc.
  • Integrated DNA Technologies, Inc.
  • Perkin Elmer, Inc.
  • RainDance Technologies, Inc.
  • Genomatix GmbH

Report Scope

In this report, the Global Targeted Sequencing And Resequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Targeted Sequencing And Resequencing Market, By Technology

  • Sequencing
  • Re-sequencing( Electrophoresis-based resequencing, NGS, Array-based resequencing)

Targeted Sequencing And Resequencing Market, By Type

  • DNA-based targeted sequencing
  • RNA-based targeted sequencing

Targeted Sequencing And Resequencing Market, By Application

  • Clinical application
  • Plant and animal sciences
  • Drug development
  • Others

Targeted Sequencing And Resequencing Market, By End use

  • Hospitals & clinics
  • Academic research
  • Others

Targeted Sequencing And Resequencing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Targeted Sequencing And Resequencing Market.

Available Customizations:

Global Targeted Sequencing And Resequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Targeted Sequencing And Resequencing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Sequencing, Re-sequencing( Electrophoresis-based resequencing, NGS, Array-based resequencing))
    • 5.2.2. By Type (DNA-based targeted sequencing, RNA-based targeted sequencing)
    • 5.2.3. By Application (Clinical application, Plant and animal sciences, Drug development, Others)
    • 5.2.4. By End use (Hospitals & clinics, Academic research, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Targeted Sequencing And Resequencing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Type
    • 6.2.3. By Application
    • 6.2.4. By End use
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Targeted Sequencing And Resequencing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End use
    • 6.3.2. Canada Targeted Sequencing And Resequencing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End use
    • 6.3.3. Mexico Targeted Sequencing And Resequencing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End use

7. Europe Targeted Sequencing And Resequencing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Type
    • 7.2.3. By Application
    • 7.2.4. By End use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Targeted Sequencing And Resequencing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End use
    • 7.3.2. France Targeted Sequencing And Resequencing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End use
    • 7.3.3. United Kingdom Targeted Sequencing And Resequencing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End use
    • 7.3.4. Italy Targeted Sequencing And Resequencing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End use
    • 7.3.5. Spain Targeted Sequencing And Resequencing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End use

8. Asia Pacific Targeted Sequencing And Resequencing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Type
    • 8.2.3. By Application
    • 8.2.4. By End use
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Targeted Sequencing And Resequencing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End use
    • 8.3.2. India Targeted Sequencing And Resequencing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End use
    • 8.3.3. Japan Targeted Sequencing And Resequencing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End use
    • 8.3.4. South Korea Targeted Sequencing And Resequencing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End use
    • 8.3.5. Australia Targeted Sequencing And Resequencing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End use

9. Middle East & Africa Targeted Sequencing And Resequencing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Type
    • 9.2.3. By Application
    • 9.2.4. By End use
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Targeted Sequencing And Resequencing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End use
    • 9.3.2. UAE Targeted Sequencing And Resequencing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End use
    • 9.3.3. South Africa Targeted Sequencing And Resequencing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End use

10. South America Targeted Sequencing And Resequencing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Type
    • 10.2.3. By Application
    • 10.2.4. By End use
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Targeted Sequencing And Resequencing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End use
    • 10.3.2. Colombia Targeted Sequencing And Resequencing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End use
    • 10.3.3. Argentina Targeted Sequencing And Resequencing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Targeted Sequencing And Resequencing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Agilent Technologies Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Illumina, Inc.
  • 15.3. F. Hoffmann-La Roche Ltd
  • 15.4. Thermo Fisher Scientific, Inc.
  • 15.5. DNASTAR Inc.
  • 15.6. Bio-Rad Laboratories, Inc.
  • 15.7. Integrated DNA Technologies, Inc.
  • 15.8. Perkin Elmer, Inc.
  • 15.9. RainDance Technologies, Inc.
  • 15.10. Genomatix GmbH

16. Strategic Recommendations

17. About Us & Disclaimer